Axel Bolte
CIK 1579247 · Chief Executive Officer · last filed 2025-07-03
Axel Bolte is a Chief Executive Officer who has filed 28 SEC Form 4 insider transactions across 5 companies since 2013. Across all open-market trades the lifetime net is +$700.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.50M
5
28
$700.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Inozyme Pharma, Inc. (INZY) Delisted | Director | 423,926 | $4.00 | $1.70M | $250.0K | 12 | 2025-05-20 |
| IVERIC bio, Inc. (ISEE) Delisted | Director | 22,088 | $39.95 | $882.4K | $0 | 6 | 2023-05-19 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | 0 | — | — | $150.6K | 6 | 2018-07-11 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | — | $0.07 | — | $0 | 1 | 2018-06-12 |
| PTCT | Director | 20,000 | $75.14 | $1.50M | $300.0K | 1 | 2013-06-27 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-03 | — | Mixed | −423,926 | -$1.70M | |
| 2025-05-20 | Inozyme Pharma, Inc. (INZY) Delisted | Exer (M) | +157,230 | $154.1K | EDGAR |
| 2024-06-20 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-13 | — | Disp (D) | −22,088 | $0 | |
| 2023-06-15 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | IVERIC bio, Inc. (ISEE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-15 | IVERIC bio, Inc. (ISEE) Delisted | Exer (M) | +14,588 | $0 | EDGAR |
| 2023-05-03 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-04 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +4,806 | $10.6K | EDGAR |
| 2022-10-04 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +3,315 | $7.6K | EDGAR |